Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)


Cooper, H.L., Healy, E., Theaker, J.M. and Friedmann, P.S. (2003) Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) Clinical and Experimental Dermatology, 28, (4), pp. 366-368. (doi:10.1046/j.1365-2230.2003.01283.x).

Download

Full text not available from this repository.

Description/Abstract

We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1046/j.1365-2230.2003.01283.x
ISSNs: 0307-6938 (print)
Related URLs:
Subjects:
ePrint ID: 27003
Date :
Date Event
July 2003Published
Date Deposited: 26 Apr 2006
Last Modified: 16 Apr 2017 22:31
Further Information:Google Scholar
URI: http://eprints.soton.ac.uk/id/eprint/27003

Actions (login required)

View Item View Item